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The study aimed to identify mechanosensitive pathways and gene networks that are stimulated by elevated cyclic pressure in aortic
valve interstitial cells (VICs) and lead to detrimental tissue remodeling and/or pathogenesis. Porcine aortic valve leaﬂets were
exposed to cyclic pressures of 80 or 120mmHg, corresponding to diastolic transvalvular pressure in normal and hypertensive
conditions, respectively. Linear, two-cycle ampliﬁcation of total RNA, followed by microarray was performed for transcriptome
analysis (with qRT-PCR validation). A combination of systems biology modeling and pathway analysis identiﬁed novel genes and
molecularmechanismsunderlyingthebiologicalresponseofVICstoelevatedpressure.56genetranscriptsrelatedtoinﬂammatory
response mechanisms were diﬀerentially expressed. TNF-α,I L - 1 α,a n dI L - 1 β were key cytokines identiﬁed from the gene network
model. Also of interest was the discovery that pentraxin 3 (PTX3) was signiﬁcantly upregulated under elevated pressure conditions
(41-fold change). In conclusion, a gene network model showing diﬀerentially expressed inﬂammatory genes and their interactions
in VICs exposed to elevated pressure has been developed. This system overview has detected key molecules that could be targeted
for pharmacotherapy of aortic stenosis in hypertensive patients.
1.Introduction
The pathogenesis of aortic stenosis (AS) is a largely under-
studied research area, compared to other cardiovascular
diseases, which has major human health implications. His-
torically, AS has been considered an age-related, passive,
degenerative disease. However, during the past 15 years,
indisputable evidence has shown that AS is an active, cell-
mediated process. Nonrheumatic AS is characterized by
chronic inﬂammation, increased extracellular matrix (ECM)
remodeling, proliferation, and diﬀerentiation of valvular in-
terstitial cells (VICs) and the development of calciﬁc lesions
on the valve [1, 2]. Nonrheumatic AS is preceded by aortic
sclerosis, a condition of valve thickening in which left
ventricular outﬂow is not obstructed. Aortic sclerosis is
associated with a 50% increase in death from all cardiovas-
cular causes and increases the risk of myocardial infarction,
heart failure, and stroke [3]. Progressive AS, in which ob-
struction to left ventricle outﬂow is present, produces left
ventricularhypertrophy,leftventriculardiastolicandsystolic
dysfunction, congestive heart failure, angina, arrhythmias,
and syncope [4]. Severe symptomatic AS is associated with
a life expectancy of less than 5 years [5]. In 2009, AS was
directly responsible for over 13,752 American deaths and
was an underlying factor in an additional 27,380 deaths and
49,000 hospital discharges. Though the disease is associated
with signiﬁcant clinical consequences, there is currently no
eﬀective therapy for valve disease other than surgical aortic
valve replacement [6].2 International Journal of Inﬂammation
In vivo studies have shown that a causal link exists bet-
ween hypertension and AS [7]. This is supported by numer-
ous in vitro studies that have shown that elevated cyclic
pressure plays an important role in valve ECM synthesis,
proinﬂammatory and cathepsin gene expression [8–11]. In
addition, it has been reported that transvalvular pressure
has a direct eﬀect on VIC stiﬀness and collagen synthesis
[12]. The potential mechanisms connecting hypertension
withinitiationandprogressionofaorticvalvediseaseinclude
(1) hypertensive pressure raises the diastolic transvalvular
pressure across the valve, increasing the mechanical strain
experienced by the leaﬂets; (2) hypertension may disturb the
hemodynamic environment (i.e., compression of the ECM,
altered ﬂow patterns), thus inﬂuencing valve cell behavior;
and (3) hypertension may play a key role in the activation of
several biological processes that induce aortic valve remodel-
ing and disease [13].
We present here the ﬁrst study of VIC gene expression
proﬁling in an ex vivo model of elevated cyclic pressure. The
data generated have enabled us to identify mechanosensitive
gene networks, and we have also investigated VIC expression
of a subset of genes associated with inﬂammation. It was
hypothesized that expression of several proinﬂammatory
genes, such as TNF-α and IL-6, would be signiﬁcantly in-
creased as clinical studies have shown these to colocalize
with calciﬁc regions in explanted aortic valves from prehy-
pertensivepatients[14].TNF-αhasalsobeenassociatedwith
matrix remodeling through the expression of MMP-1 and
-3 [15]. Additionally, TNF-α and other cytokines, such as
IL-1β, express enzymes generating oxidants (O2
−) capable
of promoting low-density lipoprotein (LDL) oxidation [16].
Proteoglycans trap LDL in the tissue, and oxidative modiﬁ-
cation leads to endothelial expression of adhesion molecules
(ICAM-1 and VCAM-1) and chemoattractants (MCP-1).
2.MaterialsandMethods
2.1. Tissue Harvest. Aortic valves were collected from six
individual female Yorkshire/Hampshire pigs immediately
after death. Animals were less than 6 months of age with
a postslaughter weight of no more than 120lbs (Sansing
Meat Services, Maben, MS). Valves were rinsed twice in ice-
cold sterile Phosphate Buﬀer Saline (PBS, Sigma, St Louis,
MO) and transported to the laboratory on ice. Leaﬂets
were cut one third of the distance from the annulus. Valve
leaﬂets did not show any sign of degeneration, tearing
or calciﬁcation. To ensure that only valve interstitial cells
(VICs) were present in each sample, the endothelial cell
layer was removed from each leaﬂet surface by immersion
o fv a l v et i s s u ei nc o l l a g e n a s eI I( 2 μg/mL in serum free
DMEM, Worthington Biochemical Corp.) for 5 minutes
at 37◦C and 5% CO2. The leaﬂet surface was then gently
swabbed. Conﬁrmation that the EC had been removed was
done through Hemotoxylin and Eosin staining (Figure 1).
Valve leaﬂets were rinsed twice with PBS to remove excess
collagenase II before being incubated overnight in DMEM
supplemented with 10% Fetal Bovine Serum (FBS; Hyclone,
Logan UT) and 1% antibiotic/antimycotic solution (Sigma).
The tissue had approximate dimensions of 12mm × 15mm.
(a)
(b)
Figure 1: (a) H & E stain of a valve leaﬂet, conﬁrming that the
endothelium has been removed by 5-minute incubation with col-
lagenase II followed by gentle swabbing. (b) Positive control sample
showing an intact endothelium on a valve leaﬂet not treated with
collagenase II and gentle swabbing. 10x magniﬁcation.
2.2. Pressure Studies. To investigate the eﬀects of cyclic pres-
sure, a custom-made, computer-operated dynamic pressure
system was used. A schematic diagram and photos of the
system are shown in Figure 2. Similar ex vivo systems have
been used in the past to demonstrate changes in extracellular
matrix protein synthesis and remodeling under elevated
pressure conditions [8, 11]. Additionally, this system has
been used to demonstrate a correlation between elevated
pressure and proinﬂammatory gene expression in aortic
valve interstitial cells [9]. Leaﬂet tissue was placed in a six-
well tissue culture plate and immersed in 3ml of culture
medium.Thetissuecultureplateswereplacedinthepressure
chamber and exposed to cyclic pressures of 80mmHg or
120mmHg, corresponding to diastolic transvalvular pres-
sure in normotensive and hypertensive conditions [17],
respectively, at a frequency of 1Hz (sinusoidal wave; 0.6sec
inﬂux, 0.4sec outﬂux) for 24 hours. Figure 3 shows repre-
sentative waveforms. At low-pressure conditions, pressure
cycled between 35mmHg and 80mmHg, with amplitude
of 45mmHg. Under elevated pressure conditions, the max-
imum pressure was 120mmHg and the minimum was
25mmHg, providing amplitude of 95mmHg. The pres-
sure system exposed tissues to mechanical stimulation by
increasing the air pressure above the supernatant media. To
produce a change in the pressure within the chamber, the
pneumatic piston moved downward in the chamber space,International Journal of Inﬂammation 3
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Figure 2: (a) Schematic diagram of the pressure system. A computer controls an electropneumatic regulator (1), controlling the ﬂow of
compressed air to a pneumatic cylinder (2) the cylinder exerts a compressive force on a silicone membrane (3) reducing the volume in
the pressure chamber (4) and subsequently increasing the atmospheric pressure surrounding the leaﬂets that are in tissue culture plates
in the chamber. A pressure transducer (Omega Engineering, Inc, PX302-200GV) (5) records the internal pressure of the chamber, which
is relayed back to the computer via a load cell conditioner (Encore Electronics, Inc., Model 4025-101) (6). The voltage and the pressure
signal were acquired with a data acquisition card module (Measurement Devices, PMD1608) and monitored using an in-house developed
LabVIEW graphical user program (LabVIEW, National Instruments). The system was placed inside an incubator to maintain a 37◦C, 5%
CO2 humidiﬁed atmosphere. (b) Photograph of a six-well plate in the pressure chamber before being sealed. (c) Photograph of the sealed
pressure chamber prior to being place in the 37◦C incubator.
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Figure 3: Pressure waveforms generated from the pressure system.
and the silicone gasket was stretched downward, reducing
the volume of the chamber, and increasing the air pressure.
During experiments, the pressure chamber was placed in
an incubator at 37◦C. The pH of the culture medium was
measured prior to and after each test using a pH meter.
pH readings of culture medium ranged between 7.3–7.4,
indicating no signiﬁcant changes. Each experimental group
contained three biological replicates.
2.3. Array Experiments. Upon completion of pressure exper-
iments, each leaﬂet was rinsed twice with sterile PBS, sub-
merged in 1mL of RNA later RNA Stabilization Reagent
(Qiagen) to avoid changes in RNA expression and stored at
−80◦C until RNA extraction. Total RNA from porcine aortic
valve interstitial cells (VICs) was extracted using the RNeasy
Minikit(Qiagen,Valencia,CA)followingthemanufacturer’s
instructions and stored at −80◦C. The quantity and quality
of RNA was conﬁrmed by spectrophotometry (A260/A280
ratio) and capillary electrophoresis (2100 Bioanalyzer; Agi-
lent Technologies, Palo Alto, CA) by using an RNA 6000
Picochip kit. Target preparation for microarray analysis
was performed according to the manufacturer’s established
protocol (www.aﬀymetrix.com). Brieﬂy, a total of 100ng
of RNA from each sample was used for single-stranded
cDNA synthesis with SuperScript II reverse transcriptase and
T7-Oligo(dT) primer/Poly(A) controls (Aﬀymetrix, Santa
Clara, CA). The single-stranded cDNA was then converted
to double-stranded cDNA by using Escherichia coli DNA
polymerase I (Aﬀymetrix) for the ﬁrst cycle. From template
cDNA, biotin-labeled cRNA was prepared in an in vitro4 International Journal of Inﬂammation
Table 1: Primer sequences used for qRT-PCR.
Gene GenBank accession no. Primer sequence Size (bp)
MMP-3 NM 001166308.1 5 -TGTGGAGTTCCTGATGTTGG-3 (F)
5 -GGCTGAAGTCTCCGTGTTCT-3 (R)
240
MMP-1 NM 001166229 5 -TTTCCTGGGATTGGCAAC-3 (F)
5 -TCCTGCAGTTGAACCAGCTA-3 (R)
233
IL-6 NM 214399.1 5 -CACCAGGAACGAAAGAGAGC-3 (F)
5 -GTTTTGTCCGGAGAGGTGAA-3 (R)
204
PTX3 NM 002852.3 5 -GGGACAAGCTCTTCATCATGCT-3 (F)
5 -GTCGTCCGTGGCTTGCA-3 (R)
71
TNF-α NM 214022.1 5 -GAAGACACACCCCCGAACAGGCA-3 (F)
5 -ACGTGGGCGACGGGCTTATCT-3 (R)
379
transcription (IVT) reaction by using the MEGAscript High-
Yield Transcription Kit (Ambion Inc, Austin, TX). Following
in vitro transcription, 600ng of cRNA from each replicate
was used for the second-cycle ﬁrst-strand cDNA synthesis.
The ﬁrst-strand cDNA from the second cycle was then
converted to second-strand cDNA. From second-strand
cDNA template, biotin-labeled cRNA was prepared in an
in vitro transcription (IVT) reaction by using GeneChip
IVT Labeling Kit (Aﬀymetrix) according to the manufac-
turer’s instructions. Then 15μg of biotin-labeled cRNA was
fragmented in 1  fragmentation buﬀer solution provided
with the GeneChip Sample Cleanup Module (Aﬀymetrix)
at 94◦C for 35min. A total of 10μg of fragmented biotin-
labeled cRNA per replicate in hybridization mixture was
then hybridized to Porcine Genome Array from Aﬀymetrix
GeneChips and incubated overnight at 45◦C in a rotating
hybridization oven, all according to the manufacturer’s
instructions (Aﬀymetrix). After >16h of hybridization, the
mixture was removed, and, in several cycles, the chips were
washed with nonstringent buﬀer and stained with strepta-
vidin/phycoerythrin (SAPE) antibody solution according to
the manufacturer’s instructions by using an Aﬀymetrix FS-
450 ﬂuidics station. The data were collectedusing Aﬀymetrix
GeneChip Scanner 3300 (Aﬀymetrix). Three chips were used
for each experimental condition and the RNA for each chip
was obtained from three diﬀerent leaﬂets.
2.4. Statistical Analysis of Array Data. Microarray data was
analyzed using a mixture model approach as previously
described [18]. Brieﬂy, microarray analysis was performed
for expression diﬀerences assuming that genes in alternative
treatments are expressed or not in the following combina-
tions: (i) not expressed in either condition, (ii) expressed
only under the ﬁrst condition, (iii) expressed only under the
second condition, and (iv) expressed under both conditions,
giving rise to 4 possible clusters with two treatments. The
number of these combinations/clusters was determined by
Akaike’s Information Criterion (AIC) and the Bayesian In-
formation Criterion (BIC) [19, 20].
2.5. Gene Expression Analysis by Quantitative Real-Time Poly-
merase Chain Reaction. To conﬁrm the fold changes in gene
expression from the array data, semi-quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR) was
done to measure the relative change in mRNA expression.
Real-Time qRT-PCR was carried out with 10ng of total RNA
using a Bio-Rad iCycler thermocycler and iScript one-step
SYBR Green kit, following the manufacturer’s instructions.
Primer sequences (Table 1) were designed using Primer 3
software [14]. Sequences were selected that crossed intron/
exon boundaries to ensure the elimination of genomic DNA.
cDNA synthesis and PCR ampliﬁcation were performed
using the following steps: 50◦C for 30mins then the reaction
mixture was heated to 95◦C for 5min; a 45cycle two-step
PCR was performed consisting of 95◦C for 15s followed
by 1min at 60◦C. Following ampliﬁcation, a melt curve
was generated that conﬁrmed primer speciﬁcity. Expression
values for each gene were calculated relative to 18s mRNA
levels. The mean fold change (n=5 ) was calculated using the
2(−ΔΔCt) method.
2.6. Network Modeling of Gene Expression Data. Aﬀymetrix
probe IDs that did not belong to the null distribution based
on the mixture model analysis were mapped to Ensembl
porcine gene accessions using Ensembl Biomart [21]. To
identify the molecular functions, biological networks and
signaling pathways in VICs responsive to cyclic pressure,
pathway analysis using Ingenuity Pathways Analysis (IPA;
Ingenuity Systems, California) was carried out as described
previously [22]. Human orthologs for porcine genes (ob-
tained from Biomart) were used in IPA. IPA generated
networks that are no more than 35genes/proteins in size.
Based on the overlap between the genes in user dataset
and a reference set (which is often the entire genome), IPA
estimates the probability that genes in a network were found
together due to chance. Networks scoring ≥ 2, with >99%
conﬁdence of not being generated by chance were considered
tobesigniﬁcant.Annotationsfromscientiﬁcliteraturestored
in the Ingenuity Pathways Knowledge Base (IPKB) were used
to determine biological functions of the identiﬁed networks.
Fisher exact test was used to calculate the P-value, the
probability of each biological function/disease or pathway
being assigned by chance. A P ≤ 0.05 (adjusted for multiple
testing for statistical rigorousness) was used to select highly
signiﬁcant biological functions and pathways represented in
the gene expression datasets.International Journal of Inﬂammation 5
Table 2: Upregulated genes related to inﬂammation. All genes had a P ≤ 0.001.
Ensembl Gene ID Gene name Description Fold change
ENSSSCG00000014986 MMP3 Matrix metallopeptidase 3 (stromelysin 1,
progelatinase)
159.845
ENSSSCG00000015385 IL6 Interleukin 6 (interferon, beta 2) 117.817
ENSSSCG00000006286 SELE Selectin E 74.336
ENSSSCG00000011727 PTX3 Pentraxin 3, long 41.052
ENSSSCG00000008087 IL1B Interleukin 1, beta 20.185
ENSSSCG00000017482 CSF3 Granulocyte colony-stimulating factor
Precursor (G-CSF)
15.267
ENSSSCG00000006588 S100A9 S100 calcium binding protein A9 9.664
ENSSSCG00000008959 CXCL2 CXCL2 9.498
ENSSSCG00000008090 IL1A Interleukin 1, alpha 9.361
ENSSSCG00000017705 CCL5 Chemokine (C-C motif) ligand 5 9.339
ENSSSCG00000017721 CCL8 Chemokine (C-C motif) ligand 8 8.386
ENSSSCG00000006288 SELP Selectin P (granule membrane protein
140kDa, antigen CD62)
8.002
ENSSSCG00000014985 MMP1 Matrix metallopeptidase 1 (interstitial
collagenase)
7.976
ENSSSCG00000008953 IL8 Interleukin 8 7.279
ENSSSCG00000008957 CXCL5
Alveolar macrophage chemotactic factor
2 Precursor (Alveolar macrophage
chemotactic factor II) (AMCF-II)
7.189
ENSSSCG00000008975 CXCL9 Chemokine (C-X-C motif) ligand 9 6.687
ENSSSCG00000017723 CCL2 Chemokine (C-C motif) ligand 2 5.243
ENSSSCG00000012853 IRF7 Interferon regulatory factor 7 4.625
ENSSSCG00000013655 ICAM1 Intercellular adhesion molecule 1 4.041
ENSSSCG00000001050 EDN1 Endothelin 1 3.383
ENSSSCG00000004789 THBS1 Thrombospondin 1 3.113
ENSSSCG00000001404 TNF
T u m o rn e c r o s i sf a c t o rP r e c u r s o r
(TNF-alpha)(Tumor necrosis factor
Ligand superfamily member
2)(TNF-a)(Cachectin)
2.626
ENSSSCG00000010414 CXCL12 Chemokine (C-X-C motif) ligand 12 2.62
ENSSSCG00000000708 TNFRSF1A T u m o rn e c r o s i sf a c t o rr e c e p t o r
superfamily, member 1A
2.327
ENSSSCG00000009002 TLR2 Toll-like receptor 2 2.157
ENSSSCG00000003065 PLAUR Plasminogen activator, urokinase
receptor
1.937
ENSSSCG00000009477 EDNRB
Endothelin B receptor Precursor
(ET-B)(Endothelin receptor nonselective
type)
1.859
ENSSSCG00000011942 CD47 CD47 molecule 1.858
ENSSSCG00000001346 ABCF1 ATP-binding cassette subfamily F
member 1
1.786
ENSSSCG00000010312 PLAU Plasminogen activator, urokinase 1.747
ENSSSCG00000013181 SERPING1 Serpin peptidase inhibitor, clade G (C1
inhibitor), member 1
1.71
ENSSSCG00000007440 CD40 CD40 molecule, TNF receptor
superfamily member 5
1.674
ENSSSCG00000004156 IFNGR1 Interferon gamma receptor 1 1.66 International Journal of Inﬂammation
Table 2: Continued.
Ensembl Gene ID Gene name Description Fold change
ENSSSCG00000001849 ANPEP Alanyl (membrane) aminopeptidase 1.547
ENSSSCG00000011322 CCR1 Chemokine (C-C motif) receptor 1 1.542
ENSSSCG00000000244 PPBP
Platelet basic protein Precursor
(PBP)(C-X-C motif chemokine
7)(Small-inducible cytokine B7)
1.533
ENSSSCG00000013551 C3 Complement component 3 1.514
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Figure 4: Conﬁrmation of microarray data by real-time qRT-PCR.
The fold change in gene expression was signiﬁcantly higher in
VICs exposed to elevated pressure compared to VICs exposed to
normal cyclic pressure. ∗Represents a signiﬁcant diﬀerence between
microarray and qRT-PCR data.
3. Results
Transcriptome analysis of VICs was performed to determine
the distinct genetic proﬁle of VICs exposed to 80mmHg
(control) and 120mmHg cyclic pressure. The mixture model
method was used as a preliminary tool to cluster genes that
could be important for the biology under investigation. In
this analysis, 3 clusters with 49.8% of the diﬀerences in
the null cluster were found, meaning that approximately
50% of the transcriptome was impacted by treatments to
s o m ed e g r e e .H o w e v e r ,o n l y∼6,000 of those genes could be
diﬀerentiatedfromthenullclusterwithhighprobability(P<
0.0001). The microarray data was validated at the mRNA
level by qRT-PCR (Figure 4). Based on the microarray data,
we chose three genes known to be mechanosensitive and
associated with aortic stenosis: MMP-1, MMP-3, and IL-6.
Further, MMP3 and IL6 had the highest fold change detected
by microarray. qRT-PCR was also performed on PTX3 and
TNF-α, as these were key genes identiﬁed in the network
analysis.Upregulationofallﬁvegenesinresponsetoelevated
pressure found in the microarray was conﬁrmed by qRT-
PCR. There was a signiﬁcant diﬀerence in the fold change
of IL6 and TNF-α; however, microarray and qRT-PCR
both showed these genes to be upregulated in the presence
of elevated pressure. A pathway analysis using IPA was
completed to provide the basis for determining molecular
functions, pathways, and networks that were important for
the VIC response to altered pressure. IPA analysis showed
that 56genes related to inﬂammation were diﬀerentially
expressed; 35 of these genes were up regulated and 21genes
were downregulated, as shown in Tables 2 and3,r especti v el y .
At the chosen statistical thresholds, 16 networks were identi-
ﬁed. The network centered on tumor necrosis factor (TNF-
α) that included molecules involved in the inﬂammatory
response is shown in Figure 5. This network included all
genes diﬀerentially expressed by elevated pressure, as shown
in Tables 2 and 3.
4. Discussion
The limited success of antiatherosclerotic therapies and the
realization that distinct diﬀerences exist between the patho-
genesis of atherosclerosis and AS suggests that innovative
pharmacotherapies are needed. Analysis of gene expression
changes in the context of response, networks, and pathways
can expedite understanding of the molecular mechanisms
that govern the VIC response to pressure. In the present
study, novel molecular mechanisms that are activated in
VICs during exposure to elevated pressure conditions were
identiﬁed. Our results show that elevated pressure induces
a gene expression pattern in cells that is considerably similar
to that seen in aortic valve disease [1], in terms of altered
expression of ECM proteins (MMP-1, MMP-3) [23, 24]a n d
proinﬂammatory cytokines (IL-1β,I L - 6 )[ 15, 25, 26]. These
results underline the key role of hypertension as an initiating
factor in the onset of aortic valve pathogenesis. Modeling
these genes to identify networks has facilitated the discovery
of some very speciﬁc genes that could potentially be targeted
for the treatment of aortic heart valve disease.
Previous histological studies of stenotic valves show that
TNF-α and IL-6 both colocalize with ox-LDL. These tend
to localize in the ﬁbrosa at the vicinity of calciﬁed areas
[14]. Hence, the ﬁndings from the microarray data are
supported by clinical observations. Creation of the gene
network model provides a systems view of the molecular
mechanisms and enables us to identify how various genes
interact. TNF-α expression was increased under elevated
pressure conditions and appears to be a key molecule in
this network as it promotes expression of several adhesion
molecules, including E-selectin, P-selectin, and ICAM-1.International Journal of Inﬂammation 7
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Figure 5:InﬂammatorygenenetworkassociatedwithupregulationofTNFα.Inthenetwork,greenrepresentsgeneswithreducedexpression
while pink and red nodes denote a signiﬁcant increase in gene expression.
Although adhesion molecules are more typically associated
with endothelial cells, it is known that activated vascular
smooth muscle cells can express adhesion molecules as part
of the inﬂammatory process [27]. TNF-α also interacts with
the cytokines IL-1α and IL-1β. Cytokine-targeting therapy
that speciﬁcally targets TNF-α, IL-1, or IL-6 could be an
eﬀective antiinﬂammatory treatment for retarding disease
progression. IL-1α and IL-1β promote the expression of
long-chain pentraxin 3 (PTX3). Clinical studies have also
shown that PTX3 levels are elevated in AS patients [28]. The
short chain pentraxin, C-reactive protein, has been oﬀered
as an early diagnostic marker for cardiovascular diseases.
However, because it can be produced in several organs, its
reliability has been questioned. PTX3 could be a potential
alternative, especially heart valve disease, and it has been
proposed as a new candidate marker for acute and chronic
heart diseases [29]. PTX3 is also involved in controlling
inﬂammation and tissue remodeling and could therefore be
a potential candidate for early AS therapy. Recent studies
have shown that PTX3 has a nonredundant regulatory and
cardioprotective role in acute myocardial infarction in mice
[30].
The results of the present study are consistent with
our global hypothesis that elevated pressure contributes to
the development of aortic valve disease. However, certain
limitations of the present study should be acknowledged.
First, the small sample for microarray analysis may decrease
the sensitivity of the study. However, the Mean-Diﬀerence-
Mixture-Model (MD-MM) method used for statistical anal-
ysisisgenerallysuperiortoothermethodsinmostsituations.8 International Journal of Inﬂammation
Table 3: Down regulated genes related to inﬂammation. All genes had a P ≤ 0.001.
Ensembl gene ID Gene name Description Fold change
ENSSSCG00000005055 LGALS3 Lectin, galactoside-binding, soluble, 3 −1.575
ENSSSCG00000011993 PROS1 Protein S (alpha) −1.654
ENSSSCG00000011399 GNAI2
Guanine nucleotide binding protein (G
protein), alpha inhibiting activity
polypeptide 2
−1.69
ENSSSCG00000001408 AIF1
Allograft inﬂammatory factor 1
(AIF-1)(Ionized calcium-binding adapter
molecule 1)(Protein G1)
−1.715
ENSSSCG00000014310 CXCL14 Chemokine (C-X-C motif) ligand 14 −1.73
ENSSSCG00000013030 PRDX5 Peroxiredoxin 5 −1.751
ENSSSCG00000014219 CDO1 Cysteine dioxygenase, type I −1.791
ENSSSCG00000012840 CD151 CD151 molecule (Raph blood group) −1.851
ENSSSCG00000015997 PRKRA
Protein kinase, interferon-inducible
double stranded RNA dependent
activator pseudogene 1
−1.927
ENSSSCG00000006612 S100A10 S100 calcium binding protein A10 −1.937
ENSSSCG00000007982 MPG N-methylpurine-DNA glycosylase −1.949
ENSSSCG00000015570 IVNS1ABP Inﬂuenza virus NS1A binding protein −1.963
ENSSSCG00000014170 CAST Calpastatin −2.067
ENSSSCG00000006661 VPS45 Vacuolar protein sorting 45 homolog (S.
cerevisiae)
−2.105
ENSSSCG00000000125 LGALS1 Lectin, galactoside-binding, soluble, 1 −2.133
ENSSSCG00000009565 GAS6 Growth arrest-speciﬁc 6 −2.193
ENSSSCG00000008428 MSH2 MutS homolog 2 −2.509
ENSSSCG00000013252 F2 Prothrombin Precursor (EC 3.4.21.5)
(Coagulation factor II)
−2.746
ENSSSCG00000005512 C5 Complement component 5 −2.793
ENSSSCG00000017473 TOP2A Topoisomerase (DNA) II alpha 170kDa −4.029
ENSSSCG00000009330 ALOX5AP Arachidonate 5-lipoxygenase-activating
protein
−4.058
The method is particularly advantageous in situations where
there are few replicates, poor signal to noise ratios, or non-
homogenous variances [18]. Second, the amount of total
RNA isolated from tissue was insuﬃcient for microarray
analysis without nonlinear ampliﬁcation. Therefore, a two-
cycle ampliﬁcation was necessary to increase the amount
of cRNA for testing. Alternative methods of RNA isolation,
such as the Qiagen lipid kit, may alleviate this limitation in
futurestudies.Asvalveleaﬂetswereonlyexposedtopressure,
we did not address the potentially important role of other
mechanicalfactorsthatarepartofthevalvemechanicalenvi-
ronment in vivo such as tensile and compressive strain, shear
stress, and ﬂexure. When these forces are combined, they
could potentially have an antagonistic or a synergistic eﬀect.
AnotherlimitationinourstudyisourPathwayanalysisusing
IPA. While IPA helped in identifying molecular networks
responsive to elevated pressure in VICs, it failed to capture
species-speciﬁcinformationthatcouldbepertinenttoeﬀects
of pressure on VICs. Furthermore, information within IPA
knowledge base is obtained from scientiﬁc literature, and
thus gene functions and interactions are subject to the last
update of the software.
To obtain a pure population of VICs, the endothelium
was removed from leaﬂets. Endothelial denudation may have
multiple eﬀects on the biology of the tissue. It has been pro-
posed that alterations in the mechanical environment of
the leaﬂets could be transduced into a pathobiological re-
sponse via a two-way communication system between
endothelial and interstitial cells. Denudation disrupts this
communication and may expose the subendothelial intersti-
tial cells to mechanical stimuli that they do not see when
the endothelium is intact. This limitation would also be
present in cell culture; however, by using an organ culture
system, VICs were retained in their native three-dimensional
ECM. The ECM is important for the transmission of
mechanicalsignalstocellsandthus,thissystemhasadistinct
advantage over mechanical studies performed with isolated
cells. The alternative is in vivo studies. Although these have
greater physiological relevance, they do not allow for strict
mechanical characterization or isolation of the eﬀects of
pressure.
In conclusion, pressure-induced changes in the porcine
aortic valve interstitial cell transcriptome are reported. This
study provides rationale for further investigation of highlyInternational Journal of Inﬂammation 9
connected and highly regulated genes as potential therapeu-
tic targets.
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